No headlines found.
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
Globe Newswire (Tue, 24-Dec 9:30 AM ET)
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
Globe Newswire (Tue, 19-Nov 7:00 AM ET)
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Achilles Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ACHL.
As of February 19, 2025, ACHL stock price was flat at $1.39 with 499,047 million shares trading.
ACHL has a beta of 1.31, meaning it tends to be more sensitive to market movements. ACHL has a correlation of 0.05 to the broad based SPY ETF.
ACHL has a market cap of $59.36 million. This is considered a Micro Cap stock.
In the last 3 years, ACHL traded as high as $3.60 and as low as $.63.
ACHL has outperformed the market in the last year with a price return of +31.1% while the SPY ETF gained +24.1%. ACHL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +32.4% and +2.2%, respectively, while the SPY returned +4.5% and +1.9%, respectively.
ACHL support price is $1.36 and resistance is $1.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACHL shares will trade within this expected range on the day.